Innate Pharma (IPHA) Analyst & Key Data

Analyst Consensus

Buy5 analysts

Buy

Updated Sep 12, 2026

Total Analysts5

Buy

4

Hold

2

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score1.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score5.0 / 5

Valuation

Current Stock Price

$1.87

Median Target+188.77%

$5.40

Potential upside vs current price

DCF Value-108.57%

-$0.16

Potential downside vs current price

Current Stock Price

$1.87

Median Target+188.77%

$5.40

Potential upside vs current price

DCF Value-108.57%

-$0.16

Potential downside vs current price

Analyst Consensus

Buy5 analysts

Buy

Updated Sep 12, 2026

Total Analysts5

Buy

4

Hold

2

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score1.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score5.0 / 5

Valuation

Current Stock Price

$1.87

Median Target+188.77%

$5.40

Potential upside vs current price

DCF Value-108.57%

-$0.16

Potential downside vs current price

Current Stock Price

$1.87

Median Target+188.77%

$5.40

Potential upside vs current price

DCF Value-108.57%

-$0.16

Potential downside vs current price

Innate Pharma S.A.